http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/ Wed, 16 Dec 2015 13:44:17 +0000 hourly 1 https://wordpress.org/?v=4.5.3 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-119 Wed, 28 Oct 2009 12:59:47 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-119 wow,you are great!Thank you! — wow,you are great!Thank you!

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-123 Wed, 02 Sep 2009 05:38:08 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-123 Thanh,When I started in knol I never imagined we will be identifying leads through knols and our discussion shows that knol platform offers some advantages over traditional publications in peer reviewed journals.One problem may be related to IPR and the patent claims by the University and funding agency over your research funded by the industry.I suggest that you contact antiviral R&D directors of Roche and Glaxo, if they still have active R&D (Was disbanded by Roche in 2002 and Glaxo licensed Biota product)

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-121 Wed, 02 Sep 2009 05:37:12 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-121 Leads Identified — Once again thanks for sharing your latest data about antivirals in the NSC database. I tried to check the NSC numbers at the NCI CTEP site and it returned 0 results. Has this database moved to NIAID or some other place. A table about the development status of the 6 NSC analogs will be helpful although some of these structures seem to be toxic. Once again 5 * from me. This knol is not yet a part of PLoS Currents Influenza? Your data backs up CDC H1N1 clinical issolates sceening and phase II and III trial results for Peramivir.

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-125 Tue, 01 Sep 2009 22:18:28 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-125 We certainly would be happy to work with Roche and Glaxo on screening their antiviral libraries for top hits. In a separate development at http://www.astonis.com we are developing software workflow engine for drug discovery and thus can screen large libraries efficiently.And thanks for your wonderful insight.

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-127 Tue, 01 Sep 2009 08:31:57 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-127 In double blind Phase II and III clinical trials Peramivir consistently failed to show superior efficacy in comparison with placebo or Tamiflu groups. Top biomedicalhjournals shun failed trials with new drugs, resulting in few publications in peer reviewed journals. The oral formulation had low bioavailability and the im injection was probably bound to proteins, leaving too little drug in the bloodstream to neutralize H1N1. It may still get approved for Tamiflu resistent H1N1 infected patients in the ICU as rescue therapy of last resort.Roche and Glaxo should open their antiviral library for screening by your group. I have published a knol on Peramivir fyi and thanks for the link of NSC data basePeramivir: A drug for Swine Flu Pandemic Emergency Use

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-133 Mon, 31 Aug 2009 17:21:57 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-133 Please assist civilian comprehension — Doctors, professors and researchers –Could you kindly write a NY Times or CNN-style science reporter’s headline for your paper? What does your research mean to civilians or signify for influenza? 5 – 25 words, please, at high school level.I will include your headline in Swine Flu News & Influenza Times, http://knol.google.com/k/-/-/2srzofgvr8kjr/26#With gratitude,Murry

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-135 Mon, 31 Aug 2009 17:21:57 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-135 Not simplistic at all, Garry. Always an issue with fresh first-line science is the lack of maturity of the information. Earlier today, the chief moderator for PLoS Currents wrote me at another Knol:——————Dear Murry,Thanks for your comment. Please note that PLoS Currents: Influenza is a *scientific site* and therefore headlines in the style of the NY Times or CNN are not appropriate.With best wishes,Eddie Holmes(Chief Moderator)———————————————Of course, I immediately argued in favor of journalism, saying ———————————————–Thank you for your response. Respectfully, I don’t think the PLoS should actually say that to a NY Times reporter digging into research significance. You don’t want this headline:”Public Library of Science says headlines in the style of the NY Times or CNN are not appropriate”In his review of this Knol, Dr. Krishan Maggon said:”This methodology can provide us with new drugs to deal with new emerging resistant strains or slow down mutation or enhance efficacy of existing antivirals.”Speaking as a journalist, Dr. Maggon’s words denote headline-quality research. “New Drugs Deal with Emerging Resistant Strains.” This is superior to our current headline at Swine Flu News, which I wrote after reading the Knol:”Discovery of new safe and effective drugs designed to overcome drug resistance of H1N1″The collection is being featured, so civilian readership is actually being encouraged. News orgs will bookmark the collection, as they should. Rather than being a stranger in a strange land, I hope that PLoS will accept a small cultural adaption. Help us civilians (and news orgs) understand the significance of these research efforts. Nothing more sinister than that.My team includes three credentialed scientists acting as pro bono editors. We are determined to mount a respectable news gathering and interpretation effort.Best wishes and much success to you,Murry Shohat(Editorial Director, http://knol.google.com/k/-/-/2srzofgvr8kjr/26#)————————–So, we’ll act as a team, giving our science editors a chance to digest the new Knols and opine. Having said that, you and I are journalists. We can enter whatever headline we think is correct. You have access to doc if you’d like to enter your headline…

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-137 Mon, 31 Aug 2009 16:46:59 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-137 Hi Thanh and Murry, I may be being simplistic here, but given that Tamiflu is by far the best known drug in the world right now with regard to swine flu, is there not also a mass communication headline here:Scientists identify six new swine flu drugs potentially more effective than Tamiflu. I think that might grab headlines far outside the scientific realm. Best wishes, Garry

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-139 Mon, 31 Aug 2009 15:07:19 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-139 Thanks. Your headline is now part of Swine Flu News & Influenza Times.

]]> http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-141 Mon, 31 Aug 2009 14:41:28 +0000 http://currents.plos.org/influenza/article/top-hits-for-h1n1pdm-identified-by-1ipgcdmpd4knt-4/#comment-141 Hi Murry, Using computer simulation techniques, scientists screened for favorable interactions between possible drug candidates with the swine flu A/H1N1 virus and identified good leads for further drud development and testing.I hope this work.Thanh

]]>